| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/25/2010 | WO2010021928A1 Organoarsenic compounds and methods for the treatment of cancer |
| 02/25/2010 | WO2010021843A1 Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment |
| 02/25/2010 | WO2010021756A1 Methods and compositions for treatment of bone defects with placental cell populations |
| 02/25/2010 | WO2010021750A2 Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| 02/25/2010 | WO2010021693A2 Mif modulators |
| 02/25/2010 | WO2010021415A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 02/25/2010 | WO2010021389A1 Nucleic acid capable of inhibiting expression of bcl-2 protein |
| 02/25/2010 | WO2010021381A1 Fused heterocyclic derivative and use thereof |
| 02/25/2010 | WO2010021149A1 Spiro compound capable of inhibiting acid secretion |
| 02/25/2010 | WO2010021112A1 Hig2 and urlc10 epitope peptide and vaccines containing the same |
| 02/25/2010 | WO2010021111A1 Inhbb epitope peptides and vaccines containing the same |
| 02/25/2010 | WO2010020981A1 A3 adenosine receptor allosteric modulators |
| 02/25/2010 | WO2010020799A2 Composition |
| 02/25/2010 | WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists |
| 02/25/2010 | WO2010020675A1 Pyrrolopyrimidine compounds as cdk inhibitors |
| 02/25/2010 | WO2010020663A1 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
| 02/25/2010 | WO2010020601A1 Dabigatran in tumour therapy |
| 02/25/2010 | WO2010020056A1 Engineered synergistic oncolytic viral symbiosis |
| 02/25/2010 | WO2010020055A1 Small molecule inhibitors of n-terminus activation of the androgen receptor |
| 02/25/2010 | WO2010020000A1 Novel compounds and their uses in diagnosis |
| 02/25/2010 | WO2010001258A3 Inhibition of tumour growth and metastases |
| 02/25/2010 | WO2009158571A8 Heteroaryl compounds and uses thereof |
| 02/25/2010 | WO2009151569A3 Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| 02/25/2010 | WO2009148659A3 Antimalarial quinolines and methods of use thereof |
| 02/25/2010 | WO2009147214A3 Inorganic nanoparticles of high density to destroy cells in-vivo |
| 02/25/2010 | WO2009146218A8 Compounds including an anti-inflammatory pharmacore and methods of use |
| 02/25/2010 | WO2009143515A3 Treatment using continuous low dose application of sugar analogs |
| 02/25/2010 | WO2009140621A3 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 02/25/2010 | WO2009140101A3 Imidazopyridine compounds useful as mmp-13 inhibitors |
| 02/25/2010 | WO2009134443A3 Rna-induced translational silencing and cellular apoptosis |
| 02/25/2010 | WO2009128952A3 Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof |
| 02/25/2010 | WO2009126926A3 Anticancer methods employing extracts of gleditsia sinensis lam |
| 02/25/2010 | WO2009126923A3 Estrogenic extracts of anemarrhena asphodeloides bge from the liliaceae family and uses thereof |
| 02/25/2010 | WO2009118660A3 Adam-15 antibodies and immunogenic peptides |
| 02/25/2010 | WO2009115651A3 N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009109927A3 Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| 02/25/2010 | WO2009106752A3 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106751A3 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106750A3 Derivatives of 6-heterocyclic-imidazo[l,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009036092A9 Mitochondria-targeted anti-tumour agents |
| 02/25/2010 | WO2002068414A8 Analogs of thalidomide as potential angiogenesis inhibitors |
| 02/25/2010 | US20100048868 Polypeptides Having Binding Affinity for Her2 |
| 02/25/2010 | US20100048725 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 02/25/2010 | US20100048708 Tamibarotene capsule preparation |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 02/25/2010 | US20100048690 Antitumoral dihydropyran-2-one compounds |
| 02/25/2010 | US20100048685 Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
| 02/25/2010 | US20100048684 EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF |
| 02/25/2010 | US20100048676 Non-androgen dependent roles for androgen receptor in liver cancer |
| 02/25/2010 | US20100048674 Role of miRNA in T cell leukemia |
| 02/25/2010 | US20100048672 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| 02/25/2010 | US20100048666 Novel phenylacetic acid derivative |
| 02/25/2010 | US20100048663 Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents |
| 02/25/2010 | US20100048658 Fused heterocyclic compounds |
| 02/25/2010 | US20100048657 Control of malignant cells proliferation through the inhibition of casein kinase 2 |
| 02/25/2010 | US20100048639 Oxadiazole derivates as s1p1 receptor agonists |
| 02/25/2010 | US20100048638 Heparan sulfate inhibitors |
| 02/25/2010 | US20100048637 Cyclohexylamines, phenylamines and uses thereof |
| 02/25/2010 | US20100048620 Composition for treatment of undifferentiated gastric cancer |
| 02/25/2010 | US20100048618 Derivatives of 8-epiblechnic Acid and their Effects on Down-Regulation of Endothelin (ETA) receptor mRNA |
| 02/25/2010 | US20100048614 Therapeutic uses of bicyclic ligands of sigma 2 receptor |
| 02/25/2010 | US20100048609 Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| 02/25/2010 | US20100048603 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives |
| 02/25/2010 | US20100048599 Compounds As Kinase Inhibitors |
| 02/25/2010 | US20100048597 Organic Compounds and Their Uses |
| 02/25/2010 | US20100048593 Deazaflavin compounds and methods of use thereof |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048581 Thiazolyl compounds useful as kinase inhibitors |
| 02/25/2010 | US20100048575 Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 02/25/2010 | US20100048571 Organic Compounds |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048564 Fused bicyclic heteroaryl derivative |
| 02/25/2010 | US20100048561 Quinazolines for pdk1 inhibition |
| 02/25/2010 | US20100048560 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048557 Triazolopyridine JAK Inhibitor Compounds and Methods |
| 02/25/2010 | US20100048551 Tricyclic Compounds Useful as Inhibitors of Kinases |
| 02/25/2010 | US20100048549 Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 |
| 02/25/2010 | US20100048547 Pi 3-kinase inhibitors and methods of their use |
| 02/25/2010 | US20100048543 Pyrimidine compounds having ties (tek) inhibitory activity |
| 02/25/2010 | US20100048542 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 02/25/2010 | US20100048540 Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors |
| 02/25/2010 | US20100048539 Compounds and compositions as protein kinase inhibitors |
| 02/25/2010 | US20100048534 Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate |
| 02/25/2010 | US20100048533 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 02/25/2010 | US20100048529 New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048524 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| 02/25/2010 | US20100048523 Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies |
| 02/25/2010 | US20100048503 Composition for treatment of pancreatic cancer |
| 02/25/2010 | US20100048499 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| 02/25/2010 | US20100048496 Core 2 GlcNAc-T inhibitors |
| 02/25/2010 | US20100048495 Core 2 GlcNAc-T inhibitors III |
| 02/25/2010 | US20100048481 Controlled Release Composition |
| 02/25/2010 | US20100048478 Fn14/trail fusion proteins |
| 02/25/2010 | US20100048467 Cystine-Knot Fold Cytokine |
| 02/25/2010 | US20100048453 Oxazole and thiazole ppar modulator |
| 02/25/2010 | US20100047818 Diagnosis of carcinomas |
| 02/25/2010 | US20100047809 Pca3, pca3 genes, and methods of use |
| 02/25/2010 | US20100047371 Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
| 02/25/2010 | US20100047368 Compositions and methods for the treatment or prevention of chemoresistant neoplasia |